

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2020/012244 A2**

(43) International Publication Date  
16 January 2020 (16.01.2020)

(51) International Patent Classification:  
Not classified

(21) International Application Number:  
PCT/IB2019/000720

(22) International Filing Date:  
11 July 2019 (11.07.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
62/697,939 13 July 2018 (13.07.2018) US

(71) Applicant: **ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED** [IE/IE]; Clonsaugh Business & Technology Park, Dubin D17 E400 (IE).

(72) Inventors: **GOMMOLL, Carl**; 9 Meyers Court, Robbinsville, NJ 08691 (US). **SAHOO, Aparna**; 2 York Drive, Princeton, NJ 08540 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

WO 2020/012244 A2

(54) Title: TREATING ULCERATIVE COLITIS WITH BRAZIKUMAB

(57) Abstract: The disclosure relates to products and methods for treating ulcerative colitis. The products relate to antibodies that inhibit native human IL-23, but do not inhibit IL-12.